AlphAIalphai — Financial news for AI agents
SEC EDGARAUG 52 min read$CLVT

Snyder Andrew Miles sold $4.8M of CLVT (indirect holdings)

Snyder Andrew Miles sold 2,489,618 indirectly-held shares of CLARIVATE PLC (CLVT) at $1.94 ($4.83M total) across 3 trades on 2026-08-03.

Original reporting
SEC EDGAR · Snyder Andrew Miles
Published Aug 5, 2026, 4:00 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 6, 2026, 6:29 AM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
alphai market briefInsider activity
Primary signal
$CLVT
Neutral
medium confidence
Mentioned
$CLVT
Relevance
6/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$CLVTNeutralLow
01

Why it matters

The newest fact is the director’s open-market sale details (shares, price, total value) and that it was not under a pre-arranged 10b5-1 plan.

02

Market read

Traders may monitor for follow-on insider activity or broader sentiment, but there is no new operational or financial guidance in the text.

03

What to watch

The article does not state total compensation, tax obligations, or whether other insiders sold/bought around the same time, limiting inference from a single transaction.

Relevance 6/10Novelty 5/10Timing: SEC Form 4 filed Aug 5, covering Aug 3 sales.

Background

The article is an SEC Form 4 insider transaction disclosure for Clarivate PLC (CLVT).

Company-level read

Ticker impact

$CLVTNeutralMedium confidence
Context

Clarivate PLC director Snyder Andrew Miles sold 2,489,618 shares in open-market transactions at $1.94/share, per a new SEC Form 4 filed Aug 5.

Expected impact

Low likelihood of a sustained price move; any reaction is likely limited to short-term sentiment around insider selling.

Evidence & confidence

The filing discloses transaction size and price, but provides no new guidance, deal, or operational change. Also, the filing states no pre-arranged 10b5-1 plan, which can increase interpretive sensitivity, though it still does not establish a new company-specific catalyst.

Market effects

Sector

Minimal. Insider selling in a single name does not materially reset sector fundamentals.

Regional

Minimal, as the disclosure is company-specific and not a macro/regional policy event.

Global

Minimal, no cross-border deal, regulation, or supply-chain shock described.

Counterpoint

What could challenge this read

The absence of a 10b5-1 plan can be misread as bearish; the sale could be routine liquidity or tax-related, so the market reaction may overstate signal.

Key entities

  • issuer
    Clarivate PLC

    Subject of the Form 4 insider transaction disclosure (CLVT).

  • insider
    Snyder Andrew Miles

    Director who sold shares via open-market transactions; filing reports indirect holdings and post-transaction share count.

Read at source← All news

Related articles

JUL 29
$CLVTMed

Clarivate Plc Q2 2026 Earnings Call Summary

Clarivate Plc (Q2 2026) discussed its Value Creation Plan to shift from transactional to recurring subscription revenue. It plans to divest the Life Sciences & Healthcare segment by year-end 2026, targeting about 92% recurring revenue pro forma. Management cited a $269m non-cash impairment, $70m one-time costs, and expects low-end FCF due to transaction and restructuring costs.

yahoo.com6 min
JUL 29
$CLVTMed

Clarivate Reports Second Quarter 2026 Results

Clarivate Plc (NYSE: CLVT) reported Q2 2026 results for the quarter ended June 30. Total revenue fell to $587.3 million from $621.4 million a year earlier, while organic revenues declined 1.5%. Net loss widened to $268.6 million due to a $221.7 million goodwill impairment; adjusted net income was $123.1 million. The company reaffirmed its 2026 outlook and cited a Life Sciences & Healthcare divestiture.

prnewswire.com6 min
JUL 29
$CLVTMedAI 8/10

CLARIVATE PLC (CLVT): Results of Operations and Financial Condition

CLARIVATE PLC (CLVT) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 ex991q22026earningsrelease.htm EX-99.1 Ex. 99.1 Q2 2026 Earnings Release 1 Clarivate Reports Second Quarter 2026 Results — Delivers continued progress on strategic and financial priorities through Value Creation Plan — — Sharpens focus and enhances financial profile wit

SEC EDGAR 8-K4 min
JUL 12
$CLVTMedAI 8/10

Clarivate to Sell Life Sciences Unit to Altaris for $600M, Refocus Core Business

Clarivate (NYSE:CLVT) will sell its Life Sciences & Healthcare unit to Altaris for $600M to refocus on Academia & Government and Intellectual Property, according to company executives. Clarivate affirmed 2026 guidance midpoints except free cash flow, citing added transaction costs. Pro forma revenue and adjusted EBITDA would be down about $370M and $120M, but free cash flow is expected to hold.

yahoo.com5 min